The future of drug development is being reshaped by real world evidence, and TargetRWE is at the center of that transformation. In this episode, Jon Lange sits down with Ed Seguine, CEO of Target RWE and co-founder of Clinical Ink, to unpack how technology, structured data, and clinician insights are accelerating clinical trials and changing how we understand complex diseases. From unlocking the untapped value of messy EMR data to addressing ethical concerns, Ed shares how real world data can reduce trial costs, shorten timelines, and lead to better outcomes for patients.

Key Takeaways:

• Real world evidence (RWE) is becoming essential in designing and supporting clinical trials, particularly for rare and complex diseases
• Real world data can help drive efficiency and can even help address ethical concerns, including how to structure clinical trials to make sure patients are getting the benefit of the best data and insights available.
• AI will increasingly play a critical role in organizing clinical data, improving clinical decision-making without eliminating the need for clinicians